Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy Article

Open Access Industry Collaboration International Collaboration

cited authors

  • Garon, Edward B.; Scagliotti, Giorgio Vittorio; Gautschi, Oliver; Reck, Martin; Thomas, Michael; Iglesias Docampo, Lara; Kalofonos, Haralabos; Kim, Joo-Hang; Gans, Steven; Brustugun, Odd Terje; Orlov, Sergey V.; Carter, Gebra Cuyun; Zimmermann, Annamaria H.; Oton, Ana B.; Alexandris, Ekaterine; Lee, Pablo; Wolff, Katharina; Stefaniak, Victoria Jennifer; Socinski, Mark A.; Perol, Maurice

authors

Publication Date

  • January 1, 2020

webpage

published in

category

volume

  • 5

issue

  • 1